AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
INCLISIRAN
5 registrations across 3 African markets— 5 active
Markets with INCLISIRAN
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| SYBRAVA 248mg/1.5ml SOLUTION FOR INJECTION | 🇬🇭Ghana | — | active | Nov 2029 |
| SYBRAVA 248mg/1.5ml SOLUTION FOR INJECTION | 🇬🇭Ghana | — | active | Nov 2029 |
| Sybrava Solution for Injection Solution For Injection In Pre-Filled Syringe | 🇰🇪Kenya | Novartis Overseas Investment AG | active | Jul 2029 |
| SYBRAVA TM 284MG/1,5ML SI SC BTE(1SER PR) NOVARTIS Solution injectable SC en | 🇲🇬Madagascar | NOVARTIS OVERSEAS | active | — |
| SYBRAVA TM 284MG/1,5ML SI SC BTE(1SER PR) NOVARTIS Solution injectable SC en | 🇲🇬Madagascar | NOVARTIS OVERSEAS | active | — |
INCLISIRAN in Africa — Regulatory Overview
INCLISIRAN is registered across 3 African markets with 5 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Ghana, Madagascar, Kenya. AfricaRegulatory refreshes this data daily from official government sources.
Of the 5 registrations, 5 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.